DE19519056A1 - Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation - Google Patents

Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation

Info

Publication number: DE19519056A1
Authority: DE; Germany
Prior art keywords: pharmaceutical preparation; inhalation; preparation according; asthma; treatment
Prior art date: 1995-05-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

DE1995119056

Other languages

German (de)

English (en)

Inventor

Rolf Dr Eisenburger

Josef Dr Hofer

Peter Dipl Chem Dr Jank

Arnim Dr Laicher

Klaus Prof Dr Med Seibel

Friedrich Dr Stanislaus

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Astellas Deutschland GmbH

Original Assignee

Klinge Pharma GmbH and Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-24

Filing date

1995-05-24

Publication date

1997-01-16

1995-05-24 Application filed by Klinge Pharma GmbH and Co filed Critical Klinge Pharma GmbH and Co

1995-05-24 Priority to DE1995119056 priority Critical patent/DE19519056A1/de

1996-05-22 Priority to PCT/EP1996/002204 priority patent/WO1996037198A1/fr

1997-01-16 Publication of DE19519056A1 publication Critical patent/DE19519056A1/de

Status Ceased legal-status Critical Current

Links

239000000935 antidepressant agent Substances 0.000 title claims abstract description 31
229940005513 antidepressants Drugs 0.000 title claims abstract description 30
208000006673 asthma Diseases 0.000 title claims abstract description 17
238000011282 treatment Methods 0.000 title claims abstract description 17
208000023504 respiratory system disease Diseases 0.000 title claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 20
239000000203 mixture Substances 0.000 claims description 29
239000000443 aerosol Substances 0.000 claims description 23
238000009472 formulation Methods 0.000 claims description 15
239000000843 powder Substances 0.000 claims description 15
230000001430 anti-depressive effect Effects 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
239000003380 propellant Substances 0.000 claims description 8
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
239000008101 lactose Substances 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
239000008103 glucose Substances 0.000 claims description 3
UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 claims description 3
239000000654 additive Substances 0.000 claims description 2
239000000969 carrier Substances 0.000 claims 1
229960004090 maprotiline Drugs 0.000 abstract description 6
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 abstract description 5
230000000241 respiratory effect Effects 0.000 abstract description 2
239000004480 active ingredient Substances 0.000 description 17
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
238000000034 method Methods 0.000 description 9
229940076279 serotonin Drugs 0.000 description 7
239000000243 solution Substances 0.000 description 7
238000009423 ventilation Methods 0.000 description 6
206010006482 Bronchospasm Diseases 0.000 description 5
241000700198 Cavia Species 0.000 description 5
241001465754 Metazoa Species 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
-1 amoxamine Chemical compound 0.000 description 5
230000007885 bronchoconstriction Effects 0.000 description 5
230000000572 bronchospasmolytic effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
229960001340 histamine Drugs 0.000 description 5
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical class C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
230000002685 pulmonary effect Effects 0.000 description 5
230000009471 action Effects 0.000 description 4
229960000836 amitriptyline Drugs 0.000 description 4
KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 4
230000035874 hyperreactivity Effects 0.000 description 4
239000006199 nebulizer Substances 0.000 description 4
239000000725 suspension Substances 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
101800004538 Bradykinin Proteins 0.000 description 3
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 3
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 3
102100035792 Kininogen-1 Human genes 0.000 description 3
102000004108 Neurotransmitter Receptors Human genes 0.000 description 3
108090000590 Neurotransmitter Receptors Proteins 0.000 description 3
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 3
229960003914 desipramine Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000003814 drug Substances 0.000 description 3
229960004801 imipramine Drugs 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000000966 norepinephrine reuptake Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
230000029058 respiratory gaseous exchange Effects 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000000556 agonist Substances 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000007423 decrease Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
238000002663 nebulization Methods 0.000 description 2
239000002858 neurotransmitter agent Substances 0.000 description 2
229960002748 norepinephrine Drugs 0.000 description 2
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
229960001158 nortriptyline Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000004089 psychotropic agent Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
239000000126 substance Substances 0.000 description 2
230000000946 synaptic effect Effects 0.000 description 2
229960000278 theophylline Drugs 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 description 1
MHNSPTUQQIYJOT-CULRIWENSA-N (3z)-3-(6h-benzo[c][1]benzoxepin-11-ylidene)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.C1OC2=CC=CC=C2C(=C/CCN(C)C)\C2=CC=CC=C21 MHNSPTUQQIYJOT-CULRIWENSA-N 0.000 description 1
MWWSFMDVAYGXBV-MYPASOLCSA-N (7r,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.O([C@@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-MYPASOLCSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
206010003645 Atopy Diseases 0.000 description 1
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
ZNIFSRGNXRYGHF-UHFFFAOYSA-N Clonidine hydrochloride Chemical compound Cl.ClC1=CC=CC(Cl)=C1NC1=NCCN1 ZNIFSRGNXRYGHF-UHFFFAOYSA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013654 Drug abuse Diseases 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
102000000543 Histamine Receptors Human genes 0.000 description 1
108010002059 Histamine Receptors Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
QSLMDECMDJKHMQ-UHFFFAOYSA-N Maprotiline Chemical compound C12=CC=CC=C2C2(CCCNC)C3=CC=CC=C3C1CC2 QSLMDECMDJKHMQ-UHFFFAOYSA-N 0.000 description 1
229940121849 Mitotic inhibitor Drugs 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
208000005392 Spasm Diseases 0.000 description 1
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
208000030961 allergic reaction Diseases 0.000 description 1
102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
229960002519 amoxapine Drugs 0.000 description 1
QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
230000000949 anxiolytic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
229940072107 ascorbate Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
210000000621 bronchi Anatomy 0.000 description 1
230000036427 bronchial hyperreactivity Effects 0.000 description 1
239000004044 bronchoconstricting agent Substances 0.000 description 1
230000003435 bronchoconstrictive effect Effects 0.000 description 1
239000013590 bulk material Substances 0.000 description 1
230000002213 calciumantagonistic effect Effects 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
229960002925 clonidine hydrochloride Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000003828 downregulation Effects 0.000 description 1
229960005426 doxepin Drugs 0.000 description 1
ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
239000007941 film coated tablet Substances 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000011278 mitosis Effects 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
201000003631 narcolepsy Diseases 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000001561 neurotransmitter reuptake Effects 0.000 description 1
230000002474 noradrenergic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
235000021313 oleic acid Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
229960002601 protriptyline Drugs 0.000 description 1
BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
230000002295 serotoninergic effect Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000005507 spraying Methods 0.000 description 1
238000003756 stirring Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
230000005062 synaptic transmission Effects 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
238000012360 testing method Methods 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
KQTIIICEAUMSDG-UHFFFAOYSA-N tricarballylic acid Chemical compound OC(=O)CC(C(O)=O)CC(O)=O KQTIIICEAUMSDG-UHFFFAOYSA-N 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
229960002431 trimipramine Drugs 0.000 description 1
ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
AQTQHPDCURKLKT-JKDPCDLQSA-N vincristine sulfate Chemical compound OS(O)(=O)=O.C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C=O)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 AQTQHPDCURKLKT-JKDPCDLQSA-N 0.000 description 1
229960002110 vincristine sulfate Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pulmonology (AREA)
Otolaryngology (AREA)
Medicinal Preparation (AREA)

DE1995119056 1995-05-24 1995-05-24 Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation Ceased DE19519056A1 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
DE1995119056 DE19519056A1 (de)	1995-05-24	1995-05-24	Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation
PCT/EP1996/002204 WO1996037198A1 (fr)	1995-05-24	1996-05-22	Utilisation d'antidepresseurs par inhalation pour le traitement de l'asthme

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE1995119056 DE19519056A1 (de)	1995-05-24	1995-05-24	Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation

Publications (1)

Publication Number	Publication Date
DE19519056A1 true DE19519056A1 (de)	1997-01-16

Family

ID=7762764

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE1995119056 Ceased DE19519056A1 (de)	1995-05-24	1995-05-24	Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation

Country Status (2)

Country	Link
DE (1)	DE19519056A1 (fr)
WO (1)	WO1996037198A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002041883A3 (fr) *	2000-11-21	2003-12-18	Vivus Inc	Administration, au besoin, d'antidepresseurs tricycliques et d'autres antidepresseurs non inhibiteurs specifiques du recaptage de la serotonine (sri) pour traiter l'ejaculation precoce
WO2005025550A1 (fr) *	2003-09-15	2005-03-24	Vectura Limited	Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
WO2010035047A1 (fr) *	2008-09-25	2010-04-01	Pharmapatents Global Ltd.	Compositions binaires comprenant un donneur d'oxyde nitrique et un inhibiteur de l'a-smase, servant au traitement de maladies respiratoires

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7585493B2 (en)	2001-05-24	2009-09-08	Alexza Pharmaceuticals, Inc.	Thin-film drug delivery article and method of use
US7766013B2 (en)	2001-06-05	2010-08-03	Alexza Pharmaceuticals, Inc.	Aerosol generating method and device
US20070122353A1 (en)	2001-05-24	2007-05-31	Hale Ron L	Drug condensation aerosols and kits
WO2002094232A1 (fr) *	2001-05-24	2002-11-28	Alexza Molecular Delivery Corporation	Administration d'antidepresseurs par voie d'inhalation
US6737042B2 (en)	2001-05-24	2004-05-18	Alexza Molecular Delivery Corporation	Delivery of drug esters through an inhalation route
US7458374B2 (en)	2002-05-13	2008-12-02	Alexza Pharmaceuticals, Inc.	Method and apparatus for vaporizing a compound
US7090830B2 (en)	2001-05-24	2006-08-15	Alexza Pharmaceuticals, Inc.	Drug condensation aerosols and kits
US7540286B2 (en)	2004-06-03	2009-06-02	Alexza Pharmaceuticals, Inc.	Multiple dose condensation aerosol devices and methods of forming condensation aerosols
CA2576961A1 (fr)	2004-08-12	2006-03-02	Alexza Pharmaceuticals, Inc.	Dispositif de distribution de drogue par aerosol integrant des conditionnements thermiques actionnes par percussion
WO2008112661A2 (fr)	2007-03-09	2008-09-18	Alexza Pharmaceuticals, Inc.	Unité chauffante à utiliser dans un dispositif d'administration de médicament
DE102007063535A1 (de) *	2007-12-21	2009-06-25	Cycnad Gmbh & Co. Kg	Pharmazeutische Zusammensetzung zur Prophylaxe und/oder symptomatischen Behandlung von zystischer Fibrose
KR102852740B1 (ko)	2018-02-02	2025-08-29	알렉스자 파마스티칼즈, 인크.	전기적 응축 에어로졸 디바이스

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3711602A (en) *	1970-10-30	1973-01-16	Crown Zellerbach Corp	Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4910197A (en) *	1984-06-11	1990-03-20	Bar-Ilan University	Method and composition for the therapeutic and prophylactic treatment of trauma to the skin
US5284133A (en) *	1992-07-23	1994-02-08	Armstrong Pharmaceuticals, Inc.	Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9318691D0 (en) *	1993-09-09	1993-10-27	Merck Sharp & Dohme	Therapeutic agents

1995
- 1995-05-24 DE DE1995119056 patent/DE19519056A1/de not_active Ceased
1996
- 1996-05-22 WO PCT/EP1996/002204 patent/WO1996037198A1/fr not_active Ceased

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3711602A (en) *	1970-10-30	1973-01-16	Crown Zellerbach Corp	Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
US4910197A (en) *	1984-06-11	1990-03-20	Bar-Ilan University	Method and composition for the therapeutic and prophylactic treatment of trauma to the skin
US5284133A (en) *	1992-07-23	1994-02-08	Armstrong Pharmaceuticals, Inc.	Inhalation device with a dose-timer, an actuator mechanism, and patient compliance monitoring means

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BEUMER: Arzneimittelforschung (1966) 16 (10), S. 1352-1353 *
CA: Vol. 71 (1969) 111309t *
Rote Liste 1995, ab 27001 Inhaltsverzeichnis *
WÖRNER: Therapiewoche 35 (1985), 5312-15 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002041883A3 (fr) *	2000-11-21	2003-12-18	Vivus Inc	Administration, au besoin, d'antidepresseurs tricycliques et d'autres antidepresseurs non inhibiteurs specifiques du recaptage de la serotonine (sri) pour traiter l'ejaculation precoce
WO2005025550A1 (fr) *	2003-09-15	2005-03-24	Vectura Limited	Compositions pharmaceutiques permettant de traiter l'ejaculation precoce par inhalation pulmonaire
RU2362551C2 (ru) *	2003-09-15	2009-07-27	Вектура Лимитед	Фармацевтические композиции для лечения преждевременной эякуляции при помощи легочной ингаляции
WO2010035047A1 (fr) *	2008-09-25	2010-04-01	Pharmapatents Global Ltd.	Compositions binaires comprenant un donneur d'oxyde nitrique et un inhibiteur de l'a-smase, servant au traitement de maladies respiratoires

Also Published As

Publication number	Publication date
WO1996037198A1 (fr)	1996-11-28

Publication	Publication Date	Title
DE69232462T2 (de)	2002-10-10	Formoterol und budesonide enthaltende zusammensetzung
EP1178832B1 (fr)	2003-07-30	Nouvelles compositions medicamenteuses a base de bromide de tiotropium et de salmeterol
DE69523301T2 (de)	2002-07-04	Ein narkotikum enthaltende aerosolformulierung
DE60133203T3 (de)	2012-02-23	Fentanyl Zusammensetzung für nasale Anwendung
DE602004012403T2 (de)	2009-03-19	Zusammensetzungen zur beeinflussung des gewichtsverlusts
DE69526425T2 (de)	2002-12-05	Verwendung von mometasone-furoat zur behandlung von luftweg- und lungenerkrankungen
DE69811378T2 (de)	2004-02-12	Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
DE69938390T2 (de)	2009-03-05	Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes
DE69434794T2 (de)	2007-07-12	Kombination von dextromethorphan mit quinidine oder quinine sulfat zur behandlung verschiedener refraktärer störungen
DE69005951T2 (de)	1994-05-26	Medikamente enthaltend Salmeterol und Fluticason.
DE69523295T2 (de)	2002-07-11	Nasale und okulare anwendung von ketamin zur schmerzbeherrschung und entgiftung
DE69722401T2 (de)	2004-05-06	Kombinationen von vasopressin und adrenergischen wirkstoffen zur behandlung des plötzlichen herztods
DE60126599T2 (de)	2007-11-22	Cannabis enthaltende pharmazeutische zusammensetzungen
DE60019167T2 (de)	2006-05-11	Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason
DE60209511T2 (de)	2006-10-05	Zusammensetzungen zur behandlung des schnupfens, welche ipratropium und xylometazolin enthalten
DE60120104T2 (de)	2006-09-21	Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DE69224069T2 (de)	1998-07-02	Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE19519056A1 (de)	1997-01-16	Verwendung von Antidepressiva zur Behandlung von Asthma und/oder Atemwegserkrankungen mittels inhalatorischer Applikation
DE1492015A1 (de)	1969-03-06	Verbesserte Verabreichungsform pharmazeutischer Praeparate
DE69002718T2 (de)	1993-12-23	Medikamente.
EP2200603B1 (fr)	2011-06-29	Osmolytes utilisés pour traiter des affections des voies respiratoires d'origine allergique
EP0697869B1 (fr)	1999-08-18	Systemes therapeutiques transdermiques pour l'administration d'agonistes de la serotonine
EP2050435B1 (fr)	2011-05-25	Préparation pour la toux
DE112019000683T5 (de)	2020-10-15	Intranasale epinephrin-formulierungen und verfahren zur behandlung von erkrankungen
WO2009083211A2 (fr)	2009-07-09	Composition pharmaceutique destinée à la prévention et/ou au traitement symptomatique de la mucoviscidose

Legal Events

Date	Code	Title	Description
1997-01-16	OP8	Request for examination as to paragraph 44 patent law
1998-02-12	8131	Rejection